ABBV News Alert Abbvie Inc. Common Stock (ABBV) 66.21 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 66.21 $ABBV

Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST

MNK: 97.84 (-0.29), BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

Biotech Stocks Take A Beating, But Find Support
at Investor's Business Daily - Wed Dec 24, 5:24PM CST
Biotech stocks took a bath in this holiday-shortened week. The catalyst was the announcement by Express Scripts (ESRX), the nation's largest benefits manager, to use AbbVie's (ABBV) hepatitis C drug exclusively. That hurt Gilead Sciences (GILD),...
CBPO: 64.79 (-0.59), ODFL: 79.34 (+0.71), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86), CELG: 109.60 (+3.48)

Could Express Scripts Holding Company's Gilead Gamble Backfire?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 12:03PM CST
Source: CVS Health. In case you missed it, the hepatitis C community was turned on its head this past weekend with the approval of a new hepatitis C compound and a major move by a pharmacy-benefits manager to strike a long-term deal with that...
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), CVS: 97.89 (+0.02), ABBV: 66.21 (+1.86), WAG: 76.67 (+0.16)

Stocks Score Small Gains; Virgin America Takes Flight
at Investor's Business Daily - Wed Dec 24, 10:57AM CST
Stocks were filled with Christmas cheer with a little more than one hour remaining in Wednesday's shortened session. The Dow Jones industrial average and the S&P 500 were trading at all-time highs. The Nasdaq led the charge, up 0.4%. The S&P 500 and...
ESRX: 85.48 (-0.40), V: 267.63 (+2.37), VA: 41.00 (+5.19), GILD: 91.29 (+1.84), BAC: 17.98 (+0.05), SN: 9.91 (-0.71), ABBV: 66.21 (+1.86), CELG: 109.60 (+3.48)

Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), IMGN: 5.90 (+0.13), ABBV: 66.21 (+1.86)

Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers
Peter F. Way, CFA - Seeking Alpha - Wed Dec 24, 8:33AM CST
This is a market price forecast analysis It is not an analysis of medical technology, competition, or economics. We have limited competence in those areas. But we do have extensive experience in how market professionals have interpreted the likely...
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), FBT: 100.93 (+1.47), BIB: 122.51 (+3.83), XBI: 182.62 (+3.44), IBB: 299.80 (+5.12), BBH: 113.91 (+1.89), ABBV: 66.21 (+1.86)

The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 8:03AM CST
For shareholders of Gilead Sciences it's practically been a dream year . Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni. ...
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Gilead Feels The Heat Of Competition
Brendan O'Boyle - at Seeking Alpha - Wed Dec 24, 6:59AM CST

ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86)

Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:50PM CST
Pharmacy benefit manager Express Scripts (ESRX) announced an update to its National Preferred Formulary, which will now include AbbVie's (ABBV) recently approved new medication for hepatitis C, Viekira Pak.
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), CRL: 63.59 (+0.33)

AbbVie Puts The Hurt On Gilead Sciences, Closes Exclusive Deal With Express Scripts
Kal Telage - at Seeking Alpha - Tue Dec 23, 3:41PM CST

JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86)

Dow Reaches Record Close as Santa Claus Rally Hits Day 5
at The Street - Tue Dec 23, 3:04PM CST
The Dow Jones Industrial Average breaks through 18,000 on Tuesday as third-quarter GDP shows signs of better-than-expected economic health.
PSX: 72.10 (-0.46), HTZ: 24.38 (-0.09), GMCR: 137.65 (+1.10), OCN: 14.88 (-0.14), XOM: 93.78 (-0.81), NQ: 4.32 (-0.36), XLV: 68.64 (+0.50), AGO: 26.28 (+0.23), ESRX: 85.48 (-0.40), RDN: 16.78 (+0.18), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CHK: 19.84 (-0.45), ABBV: 66.21 (+1.86), CVX: 113.47 (-0.48), SWN: 28.46 (-0.46), WAG: 76.67 (+0.16), REGN: 400.12 (+6.07), XLE: 80.13 (-0.59)

Why Achillion Pharmaceuticals Shares Collapsed by 25% Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 23, 2:03PM CST
Source: Achillion Pharmaceuticals What's happening? Shares of Achillion Pharmaceuticals are crashing 25% today after the company reported mixed early stage drug trial results yesterday and following Express Scripts ' decision to remove ...
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86)

Investors Should Stay Long Stocks as Market Continues Hitting Highs
at The Street - Tue Dec 23, 2:01PM CST
The CNBC 'Fast Money Halftime' trading panel knows there could be some risks in 2015.
AMZN: 303.03 (-3.26), IBB: 299.80 (+5.12), ALSN: 33.94 (+0.05), BAC: 17.98 (+0.05), TLT: 123.95 (+0.41), GOOG: 528.77 (-1.82), ESRX: 85.48 (-0.40), SPY: 207.77 (+0.02), QQQ: 104.30 (+0.09), GILD: 91.29 (+1.84), DIA: 180.03 (unch), APA: 64.05 (-1.38), ABBV: 66.21 (+1.86), BP: 38.95 (-0.17), GOOGL: 536.93 (-1.84), IWM: 119.76 (-0.10), XLE: 80.13 (-0.59)

Dow, S&P 500 Near Session Highs After GDP Growth Smashes Expectations
at The Street - Tue Dec 23, 1:25PM CST
The Dow Jones Industrial Average breaks through 18,000 on Tuesday as third-quarter GDP shows signs of better-than-expected economic health.
GPRO: 66.41 (+4.87), GMCR: 137.65 (+1.10), OCN: 14.88 (-0.14), NQ: 4.32 (-0.36), XLV: 68.64 (+0.50), AGO: 26.28 (+0.23), ESRX: 85.48 (-0.40), RDN: 16.78 (+0.18), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CHK: 19.84 (-0.45), ABBV: 66.21 (+1.86), SWN: 28.46 (-0.46), WAG: 76.67 (+0.16), REGN: 400.12 (+6.07)

Gilead Sciences Plunges for Second Day In A Row: What Wall Street's Saying
at The Street - Tue Dec 23, 12:48PM CST
The biotech stock's shares fell again Tuesday following the news of Express Scripts' exclusive deal with AbbVie. Here's what analysts said about Gilead.
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86)

Biotech Stocks Are Falling: 3 Top Stocks to Buy
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 23, 12:41PM CST
Source: Celgene Corp. Biotechnology stocks have been one of the market's darlings over the past year. The iShares Nasdaq Biotechnology ETF  (NASDAQ: IBB) has roughly doubled the S&P 500's return over the past 5 weeks. Today though, the ETF is...
BIIB: 340.89 (+5.13), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), CELG: 109.60 (+3.48)

Toys, Department Stores Rock, But Biotechs Tumble
at Investor's Business Daily - Tue Dec 23, 11:06AM CST
The euphoria over third-quarter GDP growth of 5% evaporated Tuesday morning, leaving stocks trading mixed at midday, with the Nasdaq leading other indexes off their best levels. The Nasdaq was off 0.1% ,the S&P 500 rose 0.3% and the Dow Jones...
HAS: 55.25 (+0.03), BIIB: 340.89 (+5.13), PCYC: 121.84 (+1.15), M: 64.26 (+0.22), CELG: 109.60 (+3.48), DDS: 122.53 (+0.53), ESRX: 85.48 (-0.40), MAT: 30.22 (-0.16), GILD: 91.29 (+1.84), JCP: 6.50 (-0.24), ALXN: 181.96 (+3.09), ABBV: 66.21 (+1.86)

Gilead Falls on AbbVie and Express Scripts Deal: 3 Biotech ETFs to Watch - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 11:02AM CST
Gilead shares fell more than 10 percent in Monday trading following news that AbbVie and Express Scripts signed an exclusive Hepatitis C.
PBE: 49.81 (+0.69), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), IBB: 299.80 (+5.12), BBH: 113.91 (+1.89), ABBV: 66.21 (+1.86)

Dow Industrials Top 18,000 but Biopharma Stocks Drag Nasdaq Lower
at The Street - Tue Dec 23, 10:29AM CST
The Dow Jones Industrial Average breaks through 18,000 on Tuesday as stock markets gain.
AVP: 9.22 (-0.07), GMCR: 137.65 (+1.10), NQ: 4.32 (-0.36), SBUX: 81.27 (-0.16), AGO: 26.28 (+0.23), ESRX: 85.48 (-0.40), RDN: 16.78 (+0.18), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CHK: 19.84 (-0.45), ABBV: 66.21 (+1.86), SWN: 28.46 (-0.46), WAG: 76.67 (+0.16), REGN: 400.12 (+6.07)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 20

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 314

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 23

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 13

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 12

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 287

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

AAVantgarde's Professor Auricchio Receives Prestigious Role

Updated Category News Views 177

AAVantgarde's Professor Auricchio Achieves New Milestone MILAN, a milestone moment has arrived for AAVantgarde Bio as Professor Alberto Auricchio, the visionary Founder and Chief Scientific Officer, has been elected President of the European Society of Gene and Cell Therapy. This prestigious appointment recognizes his exceptional contributions and unwavering commitment to...

Continue Reading
How Bitcoin's Drop Affects Strategy Inc (NASDAQ: MSTR) Investors

Updated Category News Views 137

Understanding the Current Market Landscape As recent market trends demonstrate, Strategy Inc (NASDAQ: MSTR) is seeing significant activity. On one hand, the company is evidently reliant on the performance of Bitcoin. With such dependence, the fluctuations in the value of Bitcoin are crucial to the health of MSTR. This situation poses both risks and opportunities for...

Continue Reading
Significant Attorney Departures to Strengthen Association Law Firm

Updated Category News Views 99

Major Attorney Moves to Association Law Group (ALG) In a noteworthy shift within Florida's community association law landscape, several prominent attorneys have transitioned from Becker & Poliakoff to join the ranks of Association Law Group (ALG). Among them, Michael C. Gongora, Lilliana Farinas-Sabogal, and Adam Cervera are recognized for their extensive experience in...

Continue Reading
EQB's Commitment to Sustainability in Financial Services

Updated Category News Views 175

EQB Focuses on Sustainability in Its Latest Report EQB Inc. (TSX: EQB) has recently published a detailed Responsibility Report, highlighting significant strides towards its sustainability commitments. This annual report encapsulates the company's dedication to fostering an environment of innovation within the Canadian banking sector, with a particular focus on enriching...

Continue Reading
BofA's Downgrade of Sandvik: Navigating Market Pressures Ahead

Updated Category News Views 103

BofA Securities dropped a bomb on Sandvik AB back then by downgrading it from Neutral to Underperform. This move sent shockwaves through the trading floor, mainly because they saw some serious trouble brewing in Sandvik’s Machining and Manufacturing Solutions (SMMS) division. Traders were quick to pick up on the whispers about short cycle pressures that could really...

Continue Reading